Spots Global Cancer Trial Database for ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.

Official Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.

Study ID: NCT01589146

Conditions

The Primary Study Objective is to Assess the Efficacy and

Safety of Extended 4-week Heparin Prophylaxis Compared to

Prophylaxis Given for 8±2 Days After Planned Laparoscopic

Surgery for Colorectal Cancer.

The Clinical Benefit Will be Evaluated as the Difference in

the Incidence of VTE or VTE-related Death Occurring Within 30 Days

From Surgery in the Two Study Groups.

Interventions

Heparin, Low-Molecular-Weight

Study Description

Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE. The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.

Detailed Description: